Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 289

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer

Open access
Jänne, Pasi A., Baik, Christina, Su, Wu-Chou, Johnson, Melissa L., Hayashi, Hidetoshi, Nishio, Makoto, Kim, Dong-Wan, Koczywas, Marianna, Gold, Kathryn A., Steuer, Conor E., Murakami, Haruyasu, Yang, James Chih-Hsin, Kim, Sang-We, Vigliotti, Michele, Shi, Rong, Qi, Zhenhao, Qiu, Yang, Zhao, Lihui, Sternberg, David, Yu, Channing, Yu, Helena A. · 2022 · Cancer Discovery

Published version of a preprint

Abstract

Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody–drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor (TKI) therapy. Among 57 patients receiving HER3-DXd 5.6 mg/kg intravenously once every 3 weeks, the confirmed objective response rate by blinded independent central review (Response Evaluation Criteria in Solid Tumors v1.1) was 39% [95% confidence interval (CI), 26.0–52.4], and median progression-free survival was 8.2 (95% CI, 4.4–8.3) months. Responses were observed in patients with known and unknown EGFR TKI resistance mechanisms. Clinical activity was observed across a broad range of HER3 membrane expression. The most common grade ≥3 treatment-emergent adverse events were hematologic toxicities. HER3-DXd has clinical activity in EGFR TKI–resistant cancers independent of resistance mechanisms, providing an approach to treat a broad range of drug-resistant cancers. Significance: In metastatic EGFR-mutated NSCLC, after disease progression on EGFR TKI therapy, treatment approaches include genotype-directed therapy targeting a known resistance mechanism or chemotherapy. HER3-DXd demonstrated clinical activity spanning known and unknown EGFR TKI resistance mechanisms. HER3-DXd could present a future treatment option agnostic to the EGFR TKI resistance mechanism. See related commentary by Lim et al., p. 16. This article is highlighted in the In This Issue feature, p. 1

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0715

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 4

  1. 2021, Rybrevant (amivantamab) [US package insert]
  2. Haikala, 2020, EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402, Cancer Res, 80, 10.1158/1538-7445.AM2020-5192 · doi:10.1158/1538-7445.am2020-5192
  3. Yonemori, 2019, Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: updated results from a phase I/II trial, Ann Oncol, 30, iii48, 10.1093/annonc/mdz100.002 · doi:10.1093/annonc/mdz100.002
  4. Yu, 2019, Preliminary phase 1 results of U3-1402—a Novel HER3-targeted antibody-drug conjugate-in EGFR TKI-resistant EGFR-mutant NSCLC, J Thorac Oncol, 14, S336, 10.1016/j.jtho.2019.08.677 · doi:10.1016/j.jtho.2019.08.677

Cited by

See all 289

Metadata

Authors
Jänne, P. A., Baik, C., Su, W.-C., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D.-W., Koczywas, M., Gold, K. A., Steuer, C. E., Murakami, H., Yang, J. C.-H., Kim, S.-W., Vigliotti, M., Shi, R., Qi, Z., Qiu, Y., Zhao, L., Sternberg, D., Yu, C., & Yu, H. A.
Venue
Cancer Discovery
Published
2021-09-21
Volume
12
Issue
1
Pages
74-89
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3200329827
Cited by
289
References
36
FWCI
29.64
Type
journal article
Language
en
Open access
hybrid
Funders
Daiichi Sankyo, Inc. American Cancer Society (CRP-17-111-01-CDD)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0715
The paper
Jänne, P. A., Baik, C., Su, W.-C., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D.-W., Koczywas, M., Gold, K. A., Steuer, C. E., Murakami, H., Yang, J. C.-H., Kim, S.-W., Vigliotti, M., Shi, R., Qi, Z., Qiu, Y., Zhao, L., Sternberg, D., . . . Yu, H. A. (2022). Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0715

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.